MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Boston Scientific Corp.

Gesloten

SectorGezondheidszorg

100.06 -1.08

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

98.5

Max

101.16

Belangrijke statistieken

By Trading Economics

Inkomsten

-138M

562M

Verkoop

352M

4.6B

K/W

Sectorgemiddelde

80.704

63.778

EPS

0.7

Winstmarge

12.322

Werknemers

53,000

EBITDA

-41M

1B

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+18.85% upside

Dividenden

By Dow Jones

Volgende Winsten

23 apr 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-2.9B

149B

Vorige openingsprijs

101.14

Vorige sluitingsprijs

100.06

Nieuwssentiment

By Acuity

29%

71%

87 / 386 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

Boston Scientific Corp. Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

3 mrt 2025, 12:35 UTC

Acquisities, Fusies, Overnames

Boston Scientific to Buy Rest of SoniVie for Initial $360 Million

5 feb 2025, 12:23 UTC

Winsten

Boston Scientific 4Q Profit Up on Strong Cardio Device Sales

8 jan 2025, 12:33 UTC

Acquisities, Fusies, Overnames

Boston Scientific to Buy Rest of Bolt Medical for $443 Million

4 nov 2024, 13:01 UTC

Acquisities, Fusies, Overnames

Boston Scientific to Buy Medical-Technology Company Cortex

3 mrt 2025, 11:59 UTC

Acquisities, Fusies, Overnames

Boston Scientific to Pay Up to Additional $180 Million Upon Achievement of Regulatory Milestone >BSX

3 mrt 2025, 11:58 UTC

Acquisities, Fusies, Overnames

Boston Scientific to Buy Rest of SoniVie for Initial $360 Million >BSX

3 mrt 2025, 11:58 UTC

Acquisities, Fusies, Overnames

Boston Scientific Announces Agreement To Acquire SoniVie Ltd. >BSX

5 feb 2025, 21:33 UTC

Winsten

How Boston Sci Leaned On Its New Heart Device For A Fourth-Quarter Beat -- IBD

5 feb 2025, 15:20 UTC

Winsten

How Boston Sci Leaned On Its New Heart Device For A Fourth-Quarter Beat -- IBD

5 feb 2025, 11:39 UTC

Winsten

Boston Scientific Sees 1Q Organic Sales Up 14%-16% >BSX

5 feb 2025, 11:39 UTC

Winsten

Boston Scientific Sees 1Q Sales Up 17%-19% >BSX

5 feb 2025, 11:38 UTC

Winsten

Boston Scientific Sees 2025 Organic Sales Up 10%-12% >BSX

5 feb 2025, 11:38 UTC

Winsten

Boston Scientific Sees 2025 Sales Up 12.5%-14.5% >BSX

5 feb 2025, 11:37 UTC

Winsten

Boston Scientific 4Q Organic Sales Up 19.5% >BSX

5 feb 2025, 11:37 UTC

Winsten

Boston Scientific 4Q Adj EPS 70c >BSX

5 feb 2025, 11:37 UTC

Winsten

Boston Scientific Sees FY EPS $1.86-EPS $1.93 >BSX

5 feb 2025, 11:37 UTC

Winsten

Boston Scientific 4Q Sales $4.56B >BSX

5 feb 2025, 11:37 UTC

Winsten

Boston Scientific Sees FY Adj EPS $2.80-Adj EPS $2.87 >BSX

5 feb 2025, 11:37 UTC

Winsten

Boston Scientific Sees 1Q Adj EPS 66c-Adj EPS 68c >BSX

5 feb 2025, 11:37 UTC

Winsten

Boston Scientific Sees 1Q EPS 43c-EPS 45c >BSX

5 feb 2025, 11:37 UTC

Winsten

Boston Scientific 4Q EPS 38c >BSX

8 jan 2025, 12:10 UTC

Acquisities, Fusies, Overnames

Boston Scientific Sees Deal More Dilutive on GAAP Basis >BSX

8 jan 2025, 12:09 UTC

Acquisities, Fusies, Overnames

Boston Scientific Sees Deal Slightly Dilutive to Adj EPS in 2025 >BSX

8 jan 2025, 12:09 UTC

Acquisities, Fusies, Overnames

Boston Scientific to Pay Up to Another $221M After Certain Regulatory Milestones >BSX

8 jan 2025, 12:08 UTC

Acquisities, Fusies, Overnames

Boston Scientific: Deal Includes Upfront Payment of About $443M for 74% Stake Not yet Owned >BSX

8 jan 2025, 12:07 UTC

Acquisities, Fusies, Overnames

Boston Scientific: Buyout to Further Co's Strategy to Address Coronary and Peripheral Disease >BSX

8 jan 2025, 12:07 UTC

Acquisities, Fusies, Overnames

Boston Scientific: Buyout to Expand Cardiovascular Portfolio With Complementary, Differentiated Calcium Modification Platform >BSX

8 jan 2025, 12:00 UTC

Acquisities, Fusies, Overnames

Boston Scientific Announces Agreement To Acquire Bolt Medical, Inc. >BSX

25 nov 2024, 12:00 UTC

Acquisities, Fusies, Overnames

Boston Scientific Announces Agreement To Acquire Intera Oncology(R) Inc. >BSX

15 nov 2024, 13:43 UTC

Acquisities, Fusies, Overnames

Boston Scientific Closes Acquisition Of Axonics, Inc. >BSX AXNX

Peer Vergelijking

Prijswijziging

Boston Scientific Corp. Prognose

Koersdoel

By TipRanks

18.85% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 120.32 USD  18.85%

Hoogste 135 USD

Laagste 108 USD

Gebaseerd op 23 Wall Street-analisten die 12-maands prijsdoelen bieden voor Boston Scientific Corp. - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

23 ratings

22

Buy

1

Hold

0

Sell

Technische score

By Trading Central

100.73 / 102.67Steun & Weerstand

Korte Termijn

Weak Bullish Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

No Evidence

Sentiment

By Acuity

87 / 386 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Boston Scientific Corp.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.